ESG Report 2022

2 In response to the Country's requirements to is approximately 2,100m , of which the R&D a c c e l e r a t e t h e d e v e l o p m e n t o f laboratory is approximately 1,600 , including biopharmaceuticals in Country's outline of “the new drug R&D laboratory, drug screening 14th Five-Year Plan” and 2035 Vision Targets, platform laboratory, cell research laboratory, the Group established the United Bio- process development research laboratory and Technology (Hengqin Co., Ltd. ( 聯邦生物科技 quality control laboratory. On the basis of the 珠 海 橫 琴 有 限 公 司 “ Hengqin Bio- existing technology and research team of some Technology”) in the Guangdong-Macao marketed products, the Company expanded the Cooperative Traditional Chinese Medicine introduction of talents in biological investment Technology Industrial Park (“Hengqin TCM and biological R&D, deepened and expanded its Industrial Park”) in April 2022. Located in a development in the fields of diabetes drugs, national pharmaceutical industrial park, monoclonal antibody drugs, chronic disease Hengqin Bio-Technology will create a first-class management, cooperation with scientific R&D and service platform integrating scientific research institutions in Hong Kong and Macau research, academic and communication, and at in the Greater Bay Area, and carried out drug t h e s ame t i me , ma r k a n o t h e r ma j o r molecular screening, process research and breakthrough and progress of the Group in the development, clinical trials, application for area of biomedicine. registration, marketing and production, commissioned production, etc. The overall site area of Hengqin Bio-Technology 2 m ) ( ) ) ( The Group adheres to innovative research and development, continues to invest a lot of resources, and gradually increases investment in research and development. Investment in research and development during the Year was RMB594 million, representing a year-on-year increase of 27.6%. Supporting Pharmaceutical Development in the Greater Bay Area 4.1.2 R&D Investment and Achievements Investment in R&D （ RMB million ） 12 Environmental, Social and Governance Report 2022 The United Laboratories International Holdings Limited 2022 340 465 594 2021 2020